Ibrutinib
别名: PCI-32765
中文名称:依鲁替尼,伊布替尼
目录号:S2680 Purity: 99.98%
Ibrutinib是一种有效的,高选择性的Brutons tyrosine kinase (Btk)抑制剂,无细胞试验中IC50为0.5 nM,对Bmx, CSK, FGR, BRK及HCK适度有效,对EGFR, Yes, ErbB2, JAK3等作用效果较弱。Ibrutinib 可作为Btk配体用于合成包括P13I在内的一系列PROTAC。
CAS: 936563-96-1
客户使用Selleck的Ibrutinib 发表文献522篇
- Gastroenterology, 2024 S0016-5085(24)00062-3
- Immunity, 2023 56(3):547-561.e7
- Nat Immunol, 2023 10.1038/s41590-023-01656-1
- Cancer Discov, 2023 13(8):1862-1883
- Cancer Cell, 2022 S1535-6108(21)00662-0
- Sci Immunol, 2022 7(69):eabm0775
- Blood, 2022 blood.2021014304
- Cancer Cell, 2021 39(3):380-393.e8
- Immunity, 2021 54(10):2273-2287.e6
- Blood, 2021 blood.2021011787
- Cancer Cell, 2020 13;37(4):551-568e14
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 35(5):752-766
- Cancer Cell, 2019 36(2):179-193
- Cancer Cell, 2019 10.1016/j.ccell.2019.09.001
- Cancer Cell, 2019 35(2):283-296
- Nat Mater, 2019 18(3):289-297
- Gastroenterology, 2019 156(6):1890-1904
- Blood, 2019 134(21):1821-1831
- Nat Med, 2018 24(5):638-646
- Nature, 2018 560(7718):387-391
- Cell, 2018 175(1):85-100
- Cancer Cell, 2018 34(6):982-995
- Nat Cell Biol, 2018 20(5):586-596
- Blood, 2018 131(4):426-438
- Blood, 2018 132(22):2401-2405
- Blood, 2018 1;132(18):1985-1988
- Nature, 2017 542(7642):489-493
- Nature, 2017 544(7651):493-497
- Cancer Cell, 2017 31(6):833-843
- J Hematol Oncol, 2017 10(1):80
- Cancer Discov, 2017 7(9):1018-1029
- Blood, 2017 129(6):759-770
- Blood, 2017 130(14):1649-1660
- Blood, 2017 129(18):2507-2518
- Ann Oncol, 2016 27(6):1123-8
- Blood, 2016 127(4):449-57
- Blood, 2016 127(4):436-48
- Blood, 2016 128(1):82-92
- Lancet Haematol, 2015 2(5):e204-11
- Blood, 2015 10.1182/blood-2014-12-618470
- Blood, 2015 125(2):407-10
- Blood, 2015 14;125(20):3128-32
- Blood, 2015 24;126(13):1565-74
- Mol Cancer, 2014 13(1):265
- Mol Cancer, 2014 13(1):159
- Blood, 2014 123(8):1229-38
- Blood, 2014 124(26):3991-5
- Blood, 2014 123(26):4120-31
- Blood, 2014 123(6):884-93
- Cancer Cell, 2012 22(5):656-67
- Blood, 2012 120(19):3978-85
- Nat Commun, 2024 15(1):1229
- J Clin Invest, 2024 e159400
- J Clin Invest, 2024 134(8)e175199
- J Adv Res, 2024 S2090-1232(24)00366-7
- J Transl Med, 2024 22(1):622
- iScience, 2024 27(1):108667
- iScience, 2024 27(2):108926
- Int J Mol Sci, 2024 25(2)766
- Front Endocrinol (Lausanne), 2024 15:1420024
- PLoS Comput Biol, 2024 20(10):e1012488
- JID Innov, 2024 4(2):100251
- Nat Commun, 2023 14(1):2935
- J Clin Invest, 2023 133(2)e163498
- J Clin Invest, 2023 133(3)e165694
- Leukemia, 2023 10.1038/s41375-023-01984-z
- Leukemia, 2023 10.1038/s41375-023-01885-1
- J Adv Res, 2023 10.1016/j.jare.2023.10.010
- Cell Death Dis, 2023 14(10):687
- Cell Rep, 2023 42(5):112528
- Elife, 2023 12e83561
- Mol Cell Proteomics, 2023 22(3):100503
- PLoS Pathog, 2023 10.1371/journal.ppat.1011781
- Mol Oncol, 2023 10.1002/1878-0261.13386
- Hemasphere, 2023 7(8):e931
- Cells, 2023 12(9)1295
- iScience, 2023 26(4):106309
- Mol Ther Oncolytics, 2023 29:17-29
- Pharmaceutics, 2023 15(4)1148
- Am J Cancer Res, 2023 13(2):452-463
- Cancers (Basel), 2023 15(14)3618
- Cancers (Basel), 2023 15(8)2356
- J Biol Chem, 2023 299(7):104865
- Front Oncol, 2023 13:1161254
- J Clin Med, 2023 12(2)399
- Hemasphere, 2023 7(9):e938
- Nat Commun, 2022 13(1):6226
- Blood Cancer J, 2022 12(5):80
- Cell Death Differ, 2022 10.1038/s41418-022-01005-z
- Mol Ther, 2022 S1525-0016(22)00557-3
- Cancer Res, 2022 canres.0218.2021
- Proc Natl Acad Sci U S A, 2022 119(23):e2201794119
- Haematologica, 2022 10.3324/haematol.2022.280884
- Haematologica, 2022 10.3324/haematol.2022.281538
- Haematologica, 2022 107(8):1796-1814
- Cancer Immunol Res, 2022 canimm.0626.2021
- Mol Syst Biol, 2022 18(8):e10855
- Blood Adv, 2022 6(18):5494-5504
- Blood Adv, 2022 6(16):4691-4704
- Front Immunol, 2022 13:825207
- Mol Oncol, 2022 10.1002/1878-0261.13281
- Cells, 2022 11(8)1338
- Commun Biol, 2022 5(1):155
- Front Pharmacol, 2022 13:1032975
- Front Pharmacol, 2022 13:1071114
- Front Pharmacol, 2022 13:864194
- Front Cell Dev Biol, 2022 10:935023
- J Cell Mol Med, 2022 26(10):3068-3073
- J Innate Immun, 2022 1-15
- Cancers (Basel), 2022 14(13)3098
- J Nat Prod, 2022 10.1021/acs.jnatprod.1c01085
- Transl Oncol, 2022 15(1):101305
- J Pers Med, 2022 12(2)258
- Cell Signal, 2022 94:110311
- J Biol Chem, 2022 298(8):102189
- J Immunol, 2022 209(9):1662-1673
- J Immunol, 2022 209(6):1156-1164
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Mol Cell Biochem, 2022 10.1007/s11010-022-04526-w
- PLoS One, 2022 17(8):e0270416
- PLoS One, 2022 17(12):e0279060
- Cell Mol Bioeng, 2022 15(3):231-243
- Bio Protoc, 2022 12(21)e4545
- Mol Biomed, 2022 3(1):2
- Explor Target Antitumor Ther, 2022 3:37-49
- STAR Protoc, 2022 3(3):101601
- Pathologie (Heidelb, 2022 43(Suppl 1:31-35)
- Cancer Res Commun, 2022 2(1):10-27
- Res Pract Thromb Haemost, 2022 6(8):e12811
- Electronic Theses of LMU Munich, 2022
- Nat Commun, 2021 12(1):2877
- Mol Cell, 2021 S1097-2765(21)00264-1
- J Exp Med, 2021 218(11)e20201656
- Clin Cancer Res, 2021 clincanres.1067.2021
- Leukemia, 2021 10.1038/s41375-021-01326-x
- Leukemia, 2021 10.1038/s41375-021-01123-6
- J Thromb Haemost, 2021 10.1111/jth.15569
- Haematologica, 2021 10.3324/haematol.2021.278743
- Cell Rep, 2021 34(11):108870
- Cell Rep, 2021 37(11):110111
- Acta Pharmacol Sin, 2021 10.1038/s41401-020-00578-0
- Aging Cell, 2021 20(3):e13332
- Blood Adv, 2021 5(10):2467-2480
- Blood Adv, 2021 5(1):185-197
- Blood Adv, 2021 5(17):3497-3510
- Blood Adv, 2021 5(23):5060-5071
- J Transl Med, 2021 19(1):473
- Front Immunol, 2021 12:745873
- Front Immunol, 2021 12:737988
- Front Immunol, 2021 12:729951
- Thromb Haemost, 2021 121(2):192-205
- mBio, 2021 12(6):e0322821
- iScience, 2021 24(8):102871
- iScience, 2021 24(9):102931
- Int J Mol Sci, 2021 23-176
- Int J Mol Sci, 2021 22(3)1194
- Int J Mol Sci, 2021 22(23)12673
- Int J Mol Sci, 2021 22(5)2276
- Front Cell Dev Biol, 2021 9:695225
- Am J Physiol Cell Physiol, 2021 320(5):C902-C915
- Aging (Albany NY), 2021 13(17):21102-21121
- Cancers (Basel), 2021 13(9)2146
- J Biol Chem, 2021 S0021-9258(21)00238-6
- Front Oncol, 2021 11:668617
- Front Oncol, 2021 11:733848
- J Immunol, 2021 ji2000569
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Drug Metab Dispos, 2021 49(1):53-61
- Toxicol Appl Pharmacol, 2021 424:115595
- Biochem Biophys Res Commun, 2021 555:196-201
- Biochemistry, 2021 60(39):2915-2924
- Prostaglandins Other Lipid Mediat, 2021 156:106575
- PeerJ, 2021 9:e12571
- Curr Oncol, 2021 28(4):2439-2451
- Biomed Chromatogr, 2021 e5139
- Pharmazie, 2021 76(2):92-96
- Bio Protoc, 2021 11(13):e4068
- J Clin Invest, 2020 2;138448
- Blood Cancer J, 2020 10(1):12
- Leukemia, 2020 10.1038/s41375-020-0977-8
- Leukemia, 2020 14
- Leukemia, 2020 10.1038/s41375-020-01025-z
- J Exp Clin Cancer Res, 2020 39(1):228
- Blood Cancer Discov, 2020 1(1):82-95
- Proc Natl Acad Sci U S A, 2020 117(11):6092-6102
- Haematologica, 2020 haematol.2020.248112
- Haematologica, 2020 105(10):2420-2431
- Br J Cancer, 2020 18
- Cell Chem Biol, 2020 27(10):1285-1295.e4
- JCI Insight, 2020 5(19)139930
- Oncogene, 2020 10.1038/s41388-020-01394-w
- Oncogene, 2020 10.1038/s41388-020-1183-x
- Aging Cell, 2020 19(1):e13079
- Elife, 2020 9e60470
- Blood Adv, 2020 4(24):6106-6116
- Biomed Pharmacother, 2020 21;128:110133
- Blood Adv, 2020 9;4(11):2439-2450
- Blood Adv, 2020 4(18):4382-4392
- Blood Adv, 2020 4(5):819-829
- Front Immunol, 2020 11:581758
- Eur J Med Chem, 2020 190:112092
- Br J Haematol, 2020 10.1111/bjh.17139
- Br J Haematol, 2020 10.1111/bjh.16386
- Int J Cancer, 2020 10.1002/ijc.33212
- J Genet Genomics, 2020 47(7):389-395
- Clin Transl Immunology, 2020 9(7):e1156
- Cancer Cell Int, 2020 20:458
- Cancer Cell Int, 2020 19;20:58
- Int J Mol Sci, 2020 26;21(9) pii: E3065
- Cancers (Basel), 2020 2;12(5) pii: E1143
- Cancers (Basel), 2020 12(10)E2725
- Aging (Albany NY), 2020 12(16):16083-16098
- Cancers (Basel), 2020 7;12(4)
- Arthritis Res Ther, 2020 30;22(1):66
- J Biol Chem, 2020 10;295(15):5163-5174
- J Biol Chem, 2020 10.1074/jbc.RA119.011946
- J Immunol, 2020 205(10):2629-2639
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- J Immunother, 2020 43(4):107-120
- Oncol Res, 2020 10.3727/096504020X15825405463920
- Cancer Genomics Proteomics, 2020 17(1):77-89
- ScholarsArchive@OSU, 2020 51
- EJHaem, 2020 1(1):122-132
- ScholarsArchive@OSU, 2020 None
- Matter, 2019
- Nat Chem Biol, 2019 15(3):232-240
- Clin Cancer Res, 2019 25(13):3974-3985
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-2202
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-1009
- Leukemia, 2019 10.1038/s41375-019-0682-7
- Leukemia, 2019 10.1038/s41375-019-0381-4
- Leukemia, 2019 10.1038/s41375-019-0569-7
- Leukemia, 2019 10.1038/s41375-019-0556-z
- Cancer Res, 2019 79(2):360-371
- J Immunother Cancer, 2019 7(1):111
- Haematologica, 2019 104(7):e288-e292
- Haematologica, 2019 10.3324/haematol.2019.216218
- Haematologica, 2019 10.3324/haematol.2019.219550
- Haematologica, 2019 10.3324/haematol.2019.224956
- Haematologica, 2019 10.3324/haematol.2018.207183
- Haematologica, 2019 104(10):2040-2052
- Cell Rep, 2019
- JCI Insight, 2019 4(12)
- Oncogene, 2019 10.1038/s41388-019-0903-6
- Blood Adv, 2019 3(1):51-62
- Thromb Res, 2019 179:64-68
- Blood Adv, 2019 3(20):2920-2933
- Front Immunol, 2019 1.8951388889
- Br J Haematol, 2019 10.1111/bjh.16118
- Biochem Pharmacol, 2019 169:113616
- Cancer Cell Int, 2019 19:67
- Mol Med, 2019 25(1):3
- Virol Sin, 2019 10.1007/s12250-019-00145-w
- Oncotarget, 2019 10(20):1943-1956
- J Neurosci, 2019 39(44):8730-8743
- Mol Cancer Res, 2019 17(6):1365-1377
- Cancers (Basel), 2019 11(10)
- Cancers (Basel), 2019 11(6)
- Lab Invest, 2019 10.1038/s41374-019-0262-5
- Front Mol Neurosci, 2019 0.50138888889
- FASEB J, 2019 33(11):12036-12046
- Sci Rep, 2019 9(1):7193
- Sci Rep, 2019 9(1):11069
- Mol Carcinog, 2019 58(6):944-956
- J Immunol, 2019 203(8):2100-2109
- Oncol Rep, 2019 10.3892/or.2019.7282
- Cell Biochem Funct, 2019 37(3):153-160
- Invest New Drugs, 2019 10.1007/s10637-019-00837-w
- J Bone Oncol, 2019 17:100253
- J Pharm Biomed Anal, 2019 177:112871
- Biochem Biophys Res Commun, 2019 515(1):92-98
- Mol Imaging, 2019 18:1536012119870899
- Leuk Lymphoma, 2019 60(7):1632-1643
- Vet Comp Oncol, 2019 10.1111/vco.12520
- Anticancer Res, 2019 39(10):5461-5471
- Biomed Chromatogr, 2019 33(5):e4507
- Biomed Chromatogr, 2019 10.1002/bmc.4575
- Methods Mol Biol, 2019 1881:19-25
- Nat Commun, 2018 9(1):727
- Nat Commun, 2018 9(1):2434
- J Clin Invest, 2018 128(1):427-445
- J Clin Invest, 2018 128(9):4132-4147
- J Clin Invest, 2018 128(12):5517-5530
- J Exp Med, 2018 215(10):2586-2599
- Nat Chem Biol, 2018 14(3):291-298
- Pharmacol Ther, 2018 187:45-60
- Clin Cancer Res, 2018 24(6):1436-1447
- Clin Cancer Res, 2018 24(1):120-129
- Clin Cancer Res, 2018 24(4):950-962
- Clin Cancer Res, 2018 24(24):6408-6420
- Leukemia, 2018 32(4):960-970
- Haematologica, 2018 103(3):e119-e122
- Cancer Immunol Res, 2018 6(10):1150-1160
- Haematologica, 2018 103(4):679-687
- Haematologica, 2018 10.3324/haematol.2018.189399
- Haematologica, 2018 103(1):116-125
- J Neuroinflammation, 2018 15(1):271
- Cell Death Dis, 2018 9(2):86
- Arterioscler Thromb Vasc Biol, 2018 38(12):2793-2805
- Cell Chem Biol, 2018 25(1):88-99
- Oncogene, 2018 37(39):5325-5339
- JCI Insight, 2018 3(19)
- Oncogene, 2018 37(41):5520-5533
- Oncogene, 2018 37(11):1534-1550
- JCI Insight, 2018 3(22)125568
- Sci Signal, 2018 11(549)
- Front Immunol, 2018 2.4166666667
- Oncoimmunology, 2018 8(1):e1512455
- Oncoimmunology, 2018 7(4):e1341032
- Clin Chem Lab Med, 2018 56(5):e118-e120
- Br J Haematol, 2018 182(5):654-669
- Int J Cancer, 2018 142(2):322-333
- MBio, 2018 9(6)
- Biochem Pharmacol, 2018 156:291-301
- Mol Cancer Ther, 2018 17(12):2564-2574
- Mol Cancer Ther, 2018 17(10):2156-2163
- Int J Mol Sci, 2018 19(2)
- Int Immunopharmacol, 2018 58:145-153
- Oncotarget, 2018 9(31):21820-21830
- Oncotarget, 2018 9(89):35875-35890
- Oncotarget, 2018 9(41):26353-26369
- Oncotarget, 2018 9(80):35123-35140
- Oncotarget, 2018 9(40):26019-26031
- Int J Oncol, 2018 53(2):823-834
- Cancers (Basel), 2018 10(12)
- Transl Oncol, 2018 11(6):1406-1418
- Am J Physiol Lung Cell Mol Physiol, 2018 315(1):L52-L58
- Fish Shellfish Immunol, 2018 77:91-99
- Sci Rep, 2018 8(1):12046
- Sci Rep, 2018 8(1):9472
- Sci Rep, 2018 8(1):17651
- Sci Rep, 2018 8(1):14216
- Curr Med Chem, 2018 10.2174/0929867325666180622143548
- J Cell Biochem, 2018 119(7):5843-5851
- BMC Cancer, 2018 18(1):466
- PLoS One, 2018 13(2):e0193098
- PLoS One, 2018 13(11):e0207915
- PLoS One, 2018 13(8):e0200725
- J Cancer Res Clin Oncol, 2018 144(4):697-706
- J Pharmacol Exp Ther, 2018 365(3):460-466
- Dig Dis Sci, 2018 63(12):3367-3375
- Biochemistry, 2018 57(26):3564-3575
- Biochemistry, 2018 57(8):1369-1379
- Leuk Lymphoma, 2018 59(4):931-940
- Cancer Genomics Proteomics, 2018 15(3):213-223
- Adv Biol Regul, 2018 67:190-211
- Tumour Biol, 2018 40(1):1010428317731369
- Nat Chem Biol, 2017 13(2):168-173
- Am J Hematol, 2017 92(8):E138-E145
- Clin Cancer Res, 2017 23(4):1049-1059
- Clin Cancer Res, 2017 23(12):3084-3096
- Clin Cancer Res, 2017 23(10):2506-2515
- Clin Cancer Res, 2017 23(14):3734-3743
- Leukemia, 2017 31(2):350-360
- Leukemia, 2017 31(3):614-624
- J Exp Clin Cancer Res, 2017 36(1):96
- EBioMedicine, 2017 15:24-35
- Proc Natl Acad Sci U S A, 2017 114(36):E7554-E7563
- Clin Immunol, 2017 178:64-73
- Oncogene, 2017 36(32):4653-4661
- Oncogene, 2017 36(17):2366-2376
- JCI Insight, 2017 2(6):e90196
- Blood Adv, 2017 1(26):2610-2623
- Eur J Med Chem, 2017 140:421-434
- Arch Toxicol, 2017 91(8):2921-2938
- Mol Cancer Ther, 2017 16(11):2586-2597
- Mol Cancer Ther, 2017 16(10):2083-2093
- Oncotarget, 2017 8(67):111495-111507
- Oncotarget, 2017 8(69):114156-114172
- Oncotarget, 2017 8(8):12953-12967
- Oncotarget, 2017 8(35):59235-59245
- Oncotarget, 2017 8(67):111386-111395
- Oncotarget, 2017 8(46):80223-80234
- Oncotarget, 2017 8(10):16259-16274
- Oncotarget, 2017 8(22):35508-35522
- Oncotarget, 2017 8(47):81794-81802
- Oncotarget, 2017 8(25):40318-40326
- Oncotarget, 2017 8(52):90013-90027
- Oncotarget, 2017 8(45):78480-78495
- Oncotarget, 2017 8(8):12764-12774
- Oncotarget, 2017
- Oncotarget, 2017 8(1):742-756
- Oncotarget, 2017 8(68):112917-112927
- Mol Cancer Res, 2017 15(12):1692-1703
- Mol Pharm, 2017 14(11):4042-4051
- Toxicol Sci, 2017 158(1):213-226
- PLoS One, 2017 12(2):e0171427
- Virology, 2017 500:96-102
- J Pharmacol Exp Ther, 2017 361(1):140-150
- SLAS Discov, 2017 22(5):494-506
- SLAS Discov, 2017 22(7):915-922
- Int J Hematol, 2017 106(5):666-674
- Anticancer Res, 2017 37(11):6203-6209
- Cancer Genet, 2017 216-217:128-141
- Nat Commun, 2016 7:11889
- Nat Commun, 2016 7:11589
- Semin Cancer Biol, 2016 39:40-8
- J Allergy Clin Immunol, 2016 137(3):889-98
- Blood Cancer J, 2016 6:e434
- Cell Death Differ, 2016 23(2):303-12
- Cell Death Differ, 2016 23(4):628-39
- Clin Cancer Res, 2016 22(1):86-95
- Clin Cancer Res, 2016 22(7):1572-82
- Clin Cancer Res, 2016 22(24):6099-6109
- Clin Cancer Res, 2016 22(3):746-56
- Clin Cancer Res, 2016 22(16):4197-205
- Clin Cancer Res, 2016 22(11):2684-96
- Leukemia, 2016 10.1038/leu.2016.153
- Sci Signal, 2016 9(415):ra17
- Bioinformatics, 2016 32(12):i253-i261
- Cancer Sci, 2016
- Mol Cancer Ther, 2016 15(12):2835-2844
- Mol Cancer Ther, 2016 15(6):1248-60
- Front Cell Dev Biol, 2016 0.20138888889
- Oncotarget, 2016 7(25):38180-38190
- Oncotarget, 2016 7(43):70623-70638
- Oncotarget, 2016 7(5):5507-20
- Oncotarget, 2016 7(26):39784-39795
- Oncotarget, 2016 7(25):38523-38538
- Oncotarget, 2016 7(23):34785-99
- Oncotarget, 2016 7(43):69961-69975
- Oncotarget, 2016 7(48):79637-79653
- Oncotarget, 2016 8(32):52225-52236
- Oncotarget, 2016 7(3):2765-79
- Oncotarget, 2016 7(46):74807-74819
- Oncotarget, 2016 7(4):4598-610
- Oncotarget, 2016 7(45):72608-72621
- Oncotarget, 2016
- J Immunol, 2016 196(8):3385-97
- J Immunol Res, 2016 2016:5281823
- PLoS One, 2016 11(1):e0146955
- PLoS One, 2016 11(8):e0161415
- Ann Hematol, 2016 95(12):1979-1988
- Mol Med Rep, 2016 13(6):4934-8
- Leuk Res, 2016 47:1-7
- Clin Lymphoma Myeloma Leuk, 2016 16(11):593-606
- Exp Hematol, 2016 44(1):38-49
- Leuk Lymphoma, 2016 57(6):1413-22
- Cancer Genet, 2016 209(4):119-29
- Nat Commun, 2015 4.5673611111
- Nat Commun, 2015 6.1395833333
- J Clin Invest, 2015 125(12):4559-71
- J Exp Med, 2015 10.1084/jem.20141957
- J Exp Med, 2015 212(6):833-43
- Clin Cancer Res, 2015 21(9):2115-26
- Clin Cancer Res, 2015 21(16):3705-15
- Clin Cancer Res, 2015 21(7):1628-38
- Leukemia, 2015 29(2):356-68
- Proc Natl Acad Sci U S A, 2015 112(52):E7230-8
- Haematologica, 2015 100(1):77-86
- Haematologica, 2015 100(8):e302-6
- Arterioscler Thromb Vasc Biol, 2015 35(11):2326-35
- J Med Chem, 2015 58(16):6589-606
- J Med Chem, 2015 58(23):9228-37
- Apoptosis, 2015 20(7):975-85
- Int J Cancer, 2015 136(12):2761-74
- Oncotarget, 2015 6(39):42130-49
- Oncotarget, 2015 6(11):8750-9
- Oncotarget, 2015 6(29):27388-402
- Oncotarget, 2015
- Oncotarget, 2015 6(34):35247-62
- Oncotarget, 2015 6(26):22734-49
- Oncotarget, 2015
- Ann N Y Acad Sci, 2015 1362:239-249
- J Biol Chem, 2015 10.1074/jbc.M114.629527
- Sci Rep, 2015 5:12949
- Sci Rep, 2015 5:13891
- J Immunol, 2015 194(5):2439-46
- J Immunol, 2015 195(8):3890-900
- Expert Opin Drug Metab Toxicol, 2015 11(9):1371-91
- J Cell Sci, 2015 128(2):251-65
- ACS Chem Biol, 2015 10(12):2687-96
- Drug Metab Dispos, 2015 43(3):375-84
- Drug Metab Dispos, 2015 43(12):1934-7
- PLoS One, 2015 10(11):e0143685
- PLoS One, 2015 10(6):e0130195
- J Pharm Biomed Anal, 2015 107:151-8
- J Neurovirol, 2015 10.1007/s13365-015-0323-5
- J Anal Methods Chem, 2015 2015:215128
- Exp Hematol, 2015 43(5):352-363
- Nat Commun, 2014 3.4791666667
- Semin Cancer Biol, 2014 24:43-8
- J Allergy Clin Immunol, 2014 134(2):420-428
- J Allergy Clin Immunol, 2014 133(6):1644-50
- Blood Cancer J, 2014 4:e181
- Clin Cancer Res, 2014 20(6):1576-89
- Leukemia, 2014 28(6):1289-98
- Leukemia, 2014 28(12):2376-87
- J Natl Cancer Inst, 2014 106(9)
- Cancer Lett, 2014 352(1):4-14
- Cell Death Dis, 2014 5:e1528
- Gastric Cancer, 2014 10.1007/s10120-014-0444-1
- Eur J Med Chem, 2014 86C:664-675
- PLoS Pathog, 2014 10(12):e1004525
- Br J Haematol, 2014 166(6):849-61
- Cancer Cell Int, 2014 14(1):32
- Oncotarget, 2014 5(20):9930-8
- Neoplasia, 2014 16(2):147-57
- J Immunol, 2014 193(2):909-20
- Evodevo, 2014 5(1):46
- PLoS One, 2014 9(6):e98818
- J Pharm Biomed Anal, 2014 61:70-7
- J Bone Miner Metab, 2014 10.1007/s00774-014-0612-8
- Leuk Lymphoma, 2014 10.3109/10428194.2014.898760
- Assay Drug Dev Technol, 2014 12(9-10):514-26
- Drug Metab Lett, 2014 8(1):19-30
- Trends Microbiol, 2013 21(6):286-95
- J Exp Med, 2013 210(13):2887-902
- Leukemia, 2013 27(10):2096-100
- Leukemia, 2013 27(10):2094-6
- J Med Chem, 2013 56(3):1262-75
- Oncotarget, 2013 4(12):2550-66
- Cell Signal, 2013 25(1):106-12
- PLoS One, 2013 8(8): e74103
- PLoS One, 2013 8(8):e69126
- Leuk Res, 2013 37(10):1271-7
- Methods Mol Biol, 2011 685:91-109
- Thyroid, 2010 20(7):689-95
化学信息&溶解度
分子量 | 440.5 |
分子式 | C25H24N6O2 |
CAS号 | 936563-96-1 |
Smiles | C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 88 mg/mL ( 199.77 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 8 mg/mL Water : Insoluble DMSO : 88 mg/mL ( 199.77 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 88 mg/mL ( 199.77 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 88 mg/mL ( 199.77 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 18 mg/mL Water : Insoluble DMSO : 88 mg/mL ( 199.77 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 45 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
2%DMSO
40%PEG300
5%Tween80
53%ddH2O
浓度:1.76mg/ml
(4.00mM)
操作示例:以 1 mL 工作液为例,取20μL88mg/ml的澄清DMSO储备液加到400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入530μL ddH2O定容至 1 mL。工作液请现配现用!
|
|
5% DMSO
95% corn oil
浓度:1.65mg/ml
(3.75mM)
操作示例:以1 mL工作液为例,取50μL 33mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
|
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:7.5mg/ml
(17.03mM)
操作示例:以 1 mL 工作液为例,取50μL150mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
|
5%DMSO
30%PEG300
5%Tween80
60%ddH2O
浓度:10mg/ml
(22.70mM)
操作示例:以 1 mL 工作液为例,取50μL200mg/ml的澄清DMSO储备液加到300μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入600μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。